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Abstract: Background: Allergic reactions can result in life-threatening situations resulting in high
economic costs and morbidity. Therefore, more effective reagents are needed for allergy treatment.
A causal relationship has been suggested to exist between the intake of omega-3/6 fatty acids, such as
docosahexanoic acid (DHA), eicosapentanoic acid (EPA), docosapentanoic acid (DPA) and arachidonic
acid (AA), and atopic individuals suffering from allergies. In allergic cascades, the hallmark cytokine
IL-4 bind to IL-4 receptor (IL-4R) and IL-13 binds to IL-13 receptor (IL-13R), this activates the STAT6
phosphorylation pathway leading to gene activation of allergen-specific IgE antibody production by
B cells. The overall aim of this study was to characterize omega-3/6 fatty acids and their effects on
STAT6 signaling pathway that results in IgE production in allergic individuals. Methods: The fatty
acids were tested in vitro with a HEK-Blue IL-4/IL-13 reporter cell line model, transfected with a
reporter gene that produces an enzyme, secreted embryonic alkaline phosphatase (SEAP). SEAP acts
as a substitute to IgE when cells are stimulated with bioactive cytokines IL-4 and/or IL-13. Results:
We have successfully used DHA, EPA and DPA in our studies that demonstrated a decrease in SEAP
secretion, as opposed to an increase in SEAP secretion with AA treatment. A statistical Student’s
t-test revealed the significance of the results, confirming our initial hypothesis. Conclusion: We have
successfully identified and characterised DHA, EPA, DPA and AA in our allergy model. While AA
was a potent stimulator, DHA, EPA and DPA were potential inhibitors of IL-4R/IL-13R signalling,
which regulates the STAT6 induced pathway in allergic cascades. Such findings are significant in the
future design of dietary therapeutics for the treatment of allergies.
Keywords: fatty acids; atopy; cytokines; IL-4 receptor; IL-13 receptor; STAT6 pathway; IgE antibody;
SEAP; HEK-Blue
1. Introduction
Over the past few decades, there has been a dramatic rise in allergic individuals worldwide.
An increased level of allergy is leading to increased financial burdens for governments and healthcare
organizations, in addition to causing medical concern [1,2]. Allergic reactions can be as mild as a
sneeze or in some cases life-threatening, such as an anaphylactic shock [3]. Many studies have been
carried out to investigate the causal relationship between allergy and various factors that result in
atopic disease, such as genetic predisposition, lifestyle and/or environment [4,5]. The occurrence of
allergic diseases has become more prevalent in the industrialized world. There has been a marked
increase in prevalence of atopic disease in regions such as Western Europe, the US and Australasia
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during recent years. A 20-fold increase has been experienced by western countries and as much as 40%
of the population suffers from this disease [6]. However, the results are skewed and more research is
needed to enhance understanding of exactly how fatty acids interact with different cells to stimulate
or inhibit the effect of allergy. Although it is known that allergies run in families, and that genetic
predisposition is the largest factor, dietary factors have also become very important in recent times [3].
The intake of certain fatty acids at a young age and their role in determining the outcome of atopic
disease in later life has been thoroughly investigated by many scientists throughout the world, via
clinical and non-clinical studies [7–12].
It has been suggested that an imbalance in dietary intake of essential fatty acids (EFA) such as
omega-3 poly-unsaturated fatty acids (n-3 PUFA) and omega-6 polyunsaturated fatty acids (n-6 PUFA)
may lead to a predisposition to allergic disease. This is usually caused by an increased intake of n-6 fatty
acids, such as linoleic acid (LA, C18:2), with a simultaneously decreased intake of omega-3 fatty acids,
such as docosahexanoic acid (DHA C22:6), eicosapentanoic acid (EPA C20:5) and docosapentanoic
acid (DPA C22:5) [13]. Such an imbalanced diet leads to an insufficiently balanced T helper cell
Types 1 and 2 (Th1 and Th2) pathways. Evidently, high cell membrane levels of arachidonic acid
(AA, C20:4n-6) stimulate a Th2 differentiation of naïve T cells, whereas membrane bound n-3 PUFA can
stimulate the Th1 variant [13]. In atopic individuals, an immune response is mounted by T cells that
are activated by allergens, promoting T helper Type 2 (Th2) variant of cells. Once stimulated, these cells
subsequently produce cytokines such as interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13
(IL-13), which stimulate B lymphocytes to produce immunoglobulin E (IgE) antibodies. Subsequently,
this reaction triggers the release of histamines and leukotrienes that result in allergic symptoms [3,14].
Unlike the cytokines produced by T helper Type 1 (Th1) cells, such as interferon-gamma (IFN-γ) and
interleukin-2 (IL-2) in non-atopic individuals, an excessive production of cytokines takes place from
Th2 cells [15].The shift in cytokine production from Th1 cells (IFN-γ and IL-2) to Th2 (IL-4, IL-5 and
IL-13) variant forms a hallmark of allergic response in atopic individuals [15].
It was recently reported in dietary intervention studies that during pregnancy n-3 PUFA show a
strong tendency to reduce serum IgE antibody levels. In a different study carried out by Weise et al. [16].
B cells treated with docosahexanoic acid (DHA) inhibited IgE production by inhibiting the STAT6
phosphorylation pathway [16]. It has also been suggested that DHA can reduce IgE production by
human B cells, by affecting the IL-4 pathway via an effect on CD40 ligand [16].
This study along with others has prompted researchers across the world to revisit the effects of
fatty acid supplements on allergic individuals. The objective of the current study was to investigate the
effect of n-3 and n-6 fatty acids on the STAT6 phosphorylation pathway that leads to the production
of IgE antibodies when stimulated by bioactive cytokines such as IL-4 and IL-13. Such findings are
significant in the future design of dietary therapeutics for the treatment of allergies.
2. Results
2.1. HEK-Blue Cell Viability Test Using Cytokines IL-4 and IL-13
A total of two sets with four assays in each set were performed using cytokines IL-4 (Figure 1)
and IL-13 (Figure 2). A dose-dependent relationship was observed between fatty acid concentration
and secreted embryonic alkaline phosphatase (SEAP) secretion from HEK-Blue cells. Blue coloration
was reduced with a gradual increase in fatty acid concentration when Quanti-blue was mixed with
cell supernatant. All positive and negative controls behaved as expected with high and low peaks
as suggested by the HEK-Blue IL-4/IL-13 kit. As hypothesized, statistically significant results were
achieved with an optimum concentration of fatty acids at 90 µM for n-3 PUFA. All inhibitions achieved
with n-3 fatty acid treatments were statistically significant with p values being less than 0.05 with a
two-tailed Student’s t-test. While DHA (Figures 1A and 2A) and EPA (Figures 1B and 2B) showed
gradual decrease in SEAP secretion with both IL-4 and IL-13, DPA (Figures 1C and 2C) showed a
sudden drop in SEAP levels suggesting a more potent inhibition. However, the treatment of HEK-Blue
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cells with n-6 PUFA AA showed no significant change in the IL-4 cytokine assay (Figure 1D). However,
an increase in SEAP secretion was observed with AA treatment when testing cells with IL-13 cytokine
(Figure 2D). Optical density readings showed no inconsistencies when n-3 fatty acids were incubated
with HEK-Blue cells without vitamin E. However, in the case of AA, it was noted that SEAP secretions
were higher than the positive control. Consistency was also observed with cell viability (results not
shown) when tested for all the treatments and compared to the positive control.
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Figure 1. IL-4 detection assay with n-3 and n-6 fatty acids (µM) with HEK-Blue Cells using Quanti-Blue.
(A,B) shows the detection assay performed with docosahexanoic acid (DHA) and eicosapentanoic
acid (EPA), respectively, with a dose-dependent inhibition; However in (C,D), a dose-dependent
inhibition does ot occur with docosapentanoic acid (DPA) and arachidonic acid (AA) but rather a
dose-response inhibition occurs. n-3 fatty acids showed no abnormal effects on secreted embryonic
alkaline phosphatase (SEAP) secretion without vitamin E. However, AA without vitamin E caused
higher than normal SEAP secretion. * p < 0.05 d notes significance of optical de sity (OD) readings
compared to positivecontrol.
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2.2. EK-Blue Ti e Course with Fatty Acid and Vita in E Treat ent
s sho n in Figures 3 and 4 a total of eight assays ere perfor ed ith four assays in each set.
Figure 3 sho s results ith cytokine IL-4 hereas Figure 4 sho s results ith cytokine IL-13.
(Figures 3 and 4 ), EP (Figures 3B and 4B) and P (Figures 3C and 4C) all sho ed a decrease
in SE P secretion and hence produced less blue coloration at 18 and 24 hours’ ti e-points hen
co pared to the positive control values. ll inhibitions achieved ith n-3 fatty acid treat ents ere
statistically significant ith p values being less than 0.05 ith a t o-tailed Student’s t-test. Since the
concentration of fatty acid was constant at 90µM, this experiment was a time-dependent inhibition of
STAT6 phosphorylation in HEK-Blue cells. However, as seen in Figures 3D and 4D, AA was shown to
increase SEAP secretion hence, it shows a higher absorption reading at 18 and 24 hours’ time-points
when compared to the positive control values. No significant change was observed at 0, 6 or 12 hours’
time-points. Cell viability was performed at the end of the 24-h incubation to observe anomalies, if
any. It was found that AA sho ed a higher cell count hen compared to positive controls in both
experiments; with cytokine IL-4 and IL-13. However, the cell viability count remained unaffected with
the treatments.
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Figure 4. HEK-Blue detection assay ith 90 µ of o ega-3 and omega-6 fatty acids with 0.15 µM
vitamin E using cytokine IL-13 as the bioactive agent. (A–C) depict a time-dependent inhibition of
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3. Discussion
Intake of pro-inflammatory omega-6 fatty acids, such as AA, may have increased in the past
few decades with a concurrent decrease in omega-3 fatty acid dietary intake. This has contributed to
an increase in allergy prevalence as well as clinical manifestations of allergic disease [17–19]. Diets
rich in fatty fish will contai relatively high levels of n-3 PUFA, as opposed to n-6 PUFA. N-3 PUFA,
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particularly DHA, EPA and DPA, exert anti-inflammatory effects, whereas n-6 fatty acids do not [20].
The purpose of this study was to {investigate the effects that n-3 and n-6 fatty acids have on STAT6
phosphorylation pathway, which leads to IgE production in B lymphocytes resulting into allergy. The
rationale of the present study was to investigate the authenticity and general observations made in
previous studies in the treatment of allergic diseases. We have shown that n-3 fatty acids DHA, EPA
and DPA all suppress and down-regulate SEAP secretion in the transfected HEK-Blue cell model
hence reducing allergy. The HEK-Blue model uses a very simple colorimetric analysis as an alternative
method to measuring IgE antibody production from B cells. Incubation with all three n-3 PUFA resulted
in a dose-dependent decrease in SEAP secretion, which in turn gave less blue color when added to
the Quant-Blue substrate. This decrease in SEAP secretion was not due to a higher cell proliferation
as demonstrated by trypan blue cell viability count. Cell viability count remained unaffected before
and after incubation of cells with treatments. The cell count range was noted to hover at a titre of
1 ˆ 105 per treated well. Positive controls were relatively higher in Figures 1 and 2 since fatty acid
treatment inhibited STAT6 phosphorylation in HEK-Blue Cells. Nevertheless, the treatment wells were
incubated for longer periods when compared to 0 h treatment in which the supernatant from the cells
was immediately used for SEAP secretion (pre-incubation period was zero as opposed to 6, 12 h, etc.).
Hence, the cells were allowed to incubate for longer and had a higher cell count compared to 0 h wells
(range remained unchanged at 1 ˆ 105).
The reason for choosing DHA, EPA and DPA for n-3 fatty acid analysis was due to their abundant
availability. Breast milk contains all three of these fatty acids and they are also found in a variety
of fish and some meat products such as beef and lamb [21]. Secondly, it is well established and
documented through clinical studies that DHA, EPA and DPA have a strong link with allergy [22].
Recent publications have reported that lower incidence of eczema was observed in children who
consumed fish and whose mothers had higher intake of fish diet during gestation period [23,24]. These
studies lead to a possible explanation of reduced SEAP secretion from HEK-Blue cells reducing clinical
symptoms in allergic individuals, which may as well be a result of less intake of Omega-3 fatty acids.
In a study carried out by Weise et al., it was found that DHA inhibited IgE production by
B lymphocytes, which are derived from human peripheral blood mononuclear cells. So far, the
underlying mechanism is unknown. Since this study was already established in the case of DHA, we
tested other n-3 PUFA, in addition to DHA, to improve the overall picture of omega-3 and omega-6
fatty acids. It is also known that IL-4R alpha (CD124) is suppressed when B lymphocytes are incubated
with n-3 fatty acids, which leads to a suppression of STAT6 phosphorylation pathway [16,20]. As
hypothesized, DHA, EPA and DPA all behaved very similarly in the time course experiment in
suppressing STAT6 signaling in HEK-Blue cells. The Janus kinase (JAK) signaling molecules activate
STAT6 transcription factor that subsequently activates gene expression in the cell nucleus. Expression
and activity of protein kinases can be altered by different fatty acids. A study carried out by Van
Meter et al. (1994) suggests that EPA and DHA can suppress the activity of protein kinase C (PKC),
which leads to inhibition of STAT6 dimerization and gene suppression [25,26]. This is a possible
explanation for less SEAP production by HEK-Blue cells. Furthermore, DHA did not exhibit a
dose-dependent inhibition in the IL-13 detection assay but rather a dose-response inhibition. With the
highest concentration of DHA, it was observed that inhibition was the highest. Literature suggests that
high dose of DHA supplementation changes the outcome of IgE production from B cells in response to
cytokine stimulation, which may explain the sudden drop in SEAP secretion at 150 µM [16,27].
The purpose of choosing AA for these studies was due to the abundance of this fatty acid in body
tissues. It is a major component of mammalian cell membranes and accounts up to a quarter of all
phospholipid fatty acid [28,29], hence making it a very important target for allergy studies because
of its ubiquitous nature. No significant change was observed in the case of AA when using a range
of concentrations. However, in the time course experiment, an increase in SEAP production was
observed, as well as slightly elevated levels of cell viability counts. This evidence is in agreement
with the fact that AA causes cell proliferation in endothelial cells and HEK-Blue cells are derived from
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endothelial cells found in kidneys [30]. It was also observed that AA incubated with HEK-Blue cells
without vitamin E supplementation gave higher SEAP secretion than the positive control. A higher
optical density reading was also observed in the case of EPA and DPA when used with IL-4 and DPA
when used with IL-13. This is not consistent with literature, which suggests that vitamin E suppresses
the production of IgE antibody from B cells and hence, it can suppress SEAP secretion by the same
mechanism. In a study carried out by Inagaki et al., vitamin E was supplemented to mice in diets along
with oral administration of sesame oil, which resulted in suppression of IgE antibody production [31].
Another clinical trial observed that dietary intake of vitamin E reduced serum IgE concentrations in
allergic individuals suffering from atopic dermatitis [32]. However, this was not true in the case of
DHA, when used with IL-4 and IL-13, and EPA with IL-13, which suggests that vitamin E may have
specific effects on STAT6 phosphorylation in combination with different fatty acids. Furthermore,
AA showed inhibition of SEAP secretion with IL-4 detection assay, which is an anomaly we found in
the overall effects of AA. This may be explained by the fact that AA incorporated into cell membranes
can affect membrane fluidity which may consequently effect cell function [20,33,34].
Another equally important explanation can be the production of inflammatory prostaglandins
from HEK-Blue cells. AA is found esterified at the sn-2 positions of membrane phospholipids. AA can
be released by cytoplasmic phospholipase A2 and converted by cyclooxygenase (COX) 1 and 2 to
prostaglandin intermediates known as PGH2. Prostaglandin synthases then convert PGH2 to 2-series
prostanoids known as prostaglandin E2 (PGE2), which are inflammatory. AA can also be converted
to thromboxanes (TX) of the 2-series for PGD2 or by 5-, 12-, and 15-LOX, which yield inflammatory
leukotrienes of the 4-series. It was found that AA was suppressing IL-13 stimulation of HEK-Blue
cells when tested with higher doses of AA. A study suggests that IL-13 suppresses COX-2 gene
expression [35]. By contrast, n-3 PUFA such as DHA and EPA can replace AA in cell membranes
and can be converted by the same enzymes to anti-inflammatory intermediates such as the 3-series
prostanoids known as prostaglandin E3 (PGE3) [20,36,37]. In fact, EPA and DHA are poor COX
substrates and potent antagonist to COX activity. Also, gene expression of proteins involved in AA
metabolism can be suppressed by the action of EPA and DHA [37]. All kidney derived cells are
capable of producing the COX series of enzymes hence, incubating cells with fatty acids can alter gene
expression through modification of transcription factor activity [38,39]. This may effect SEAP secretion
from HEK-Blue cells. Although not part of this study, it is important to mention that PGE2 receptors
regulate activation and differentiation of mouse B lymphocytes to IgE production [40].
4. Materials and Methods
4.1. Cell Culture, PUFA and Vitamin E Reagents and Buffers
HEK-Blue™ IL-4/IL-13 (InvivoGen, San Diego, CA, USA) cells allow the detection of bioactive
IL-4 and IL-13 signaling by monitoring the activation of the JAK-STAT6 phosphorylation pathway.
The cells are a result of a stably transfected human JAK-STAT6 gene. Other pathways linked to
the STAT6 pathway are naturally expressed by the cells. The cells are further transfected with a
STAT6-inducible SEAP reporter gene, as an alternative to IgE secretion in B lymphocytes, when signaled
by cytokines IL-4 or IL-13. Finally, the cells are transfected with a stably expressed recombinant type II
IL-4Rα/IL-13αR1 receptor.
Growth medium: HEK-Blue cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(GIBCO), supplemented with 10% fetal bovine serum (FBS), in a humidified incubator at 37 ˝C with 5%
CO2. Antibiotics were added to the medium to avoid contamination (50 U/mL of penicillin, 50 µg/mL
of streptomycin, 100 µg/mL of normocin, 10 µg/mL of blasticidin and 100 µg/mL of zeocin-GIBCO),
Trypsin/EDTA (0.05%; GIBCO) was used for trypsinization.
Experimental medium: Growth medium was replaced with 2 mM L-glutamine and heat
inactivated 10% FBS along with omega-3 and omega-6 fatty acids; namely, DHA (Mw 328 Da), EPA
(Mw 302 Da), DPA (Mw 330.5 Da) and AA (Mw 304.46 Da), all of which were commercially purchased
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from Invitrogen (Carlsbad, CA, USA) at a concentration of 10 µg/mL. The final concentrations prepared
were 30, 60, 90, 120 and 150 µM using 100% ethanol as the solvent. Vitamin E (Invitrogen, Carlsbad,
CA, USA) was prepared as an antioxidant to prevent oxidation of fatty acids using growth medium.
The final concentrations prepared were 0.05, 0.1, 0.15, 0.2 and 0.25 µM to all corresponding treatments
outlined above.
Initially, cells were tested in the presence of ethanol and vitamin E separately to confirm whether
cell viability and/or STAT6 phosphorylation pathway was affected or whether it caused apoptosis
in cells. Cells were incubated with experimental medium containing ethanol and vitamin E over a
period of 24 h and cell viability was tested at five intervals (0, 6, 12, 18 and 24 h). Our results confirmed
that the amounts and concentrations of ethanol and vitamin E used in our study had no effect on cell
viability and/or STAT6 phosphorylation pathway with or without the addition of ethanol and vitamin
E (results not shown). Cells were then ready to be tested with fatty acids.
Stock solutions of DHA, EPA, DPA and AA in ethanol were stored at ´20 ˝C, and then these
PUFA were pre-incubated in complete growth medium at 37 ˝C overnight to allow protein conjugation.
We tested a range of concentrations on HEK-Blue cells to establish that the STAT6 phosphorylation
pathway lead to the production of serum embryonic alkaline phosphatase (SEAP). This is an alternative
product to IgE antibody that is produced by B lymphocytes when triggered by the bioactive IL-4 or
IL-13. SEAP breaks down Quanti-Blue substrate, which gives the blue coloration. The blue color
can then be detected using a spectrophotometer. Vitamin E stock was stored at 4 ˝C and was freshly
prepared in ethanol when preparing experimental media with fatty acids.
Two sets of experiments were performed to determine the effects of fatty acids on the STAT6
phosphorylation pathway. In the preliminary experiments, a range of different concentrations of
fatty acids and vitamin E were studied to confirm their effect on SEAP production. Once confirmed,
the most optimum concentration of fatty acid was used to perform a time course experiment. Cell
viability and SEAP production were detected at five different time-points over a period of 24 h. These
experiments allowed us to study two different variables; time and concentration of fatty acid needed
to suppress SEAP secretion by HEK-Blue cells by using a very simple colorimetric analysis.
4.2. HEK-Blue Cell Viability Test Using Cytokines IL-4 and IL-13
The protocol used was taken from the datasheet provided with the HEK-Blue IL-4/IL-13 kit. A few
adjustments were made in the protocol to perform the assay without compromising the signalling
in cells. Cells were grown in T-75 flasks and used for detection assay. The cells were detached using
3 mL trypsin, which was neutralized with 7 mL of media containing FBS to give a total volume of
10 mL. The average cells were counted using a TC10 automated cell counter (Bio-Rad Laboratories,
Inc., Hercules, CA, USA). HEK-Blue cells were pipetted into 15 mL tubes, which were centrifuged at
1200 RPM for 5 min. The supernatant was discarded and experimental media was added to suspend
the cell pellet. If required, cell titre was reduced by adding growth medium to achieve optimum
cell density. The cells were pipetted into 24-well plates (Corning, Sigma-Aldrich, St. Louis, MO,
USA) at a density of ~50,000 cells per well in a total volume of 720 µL. A total of 12 treatment wells
were setup in triplicates. Cells were treated with a combination of fatty acids (30, 60, 90, 120 and
150 µM) with and without vitamin E (0.05, 0.1, 0.15, 0.2, 0.25 µM). A total of 80 µL of cytokine IL-4
(Integrated Sciences, Chatswood NSW 2067, Australia) and IL-13 (Integrated Sciences, Chatswood
NSW 2067, Australia) were pipetted to each treatment well at a concentration of 100 ng/mL. Positive
controls (PC: with cytokine stimulation) and negative controls (NC: without cytokine stimulation)
were included to provide a comparative study. Cells were incubated with the treatments for a period
of 24 h. Post-incubation, 20 µL of induced HEK-Blue IL-4/IL-13 cells supernatant from each treatment
well was added to a corresponding plate with 180 µL of Quanti-Blue substrate in each well. This was
incubated for a total of 3 h to detect SEAP levels. The blue color was detected using anxMark microplate
absorbance spectrophotometer (Bio-Rad Laboratories Inc., Hercules, CA, USA) at a wavelength of
640 nm. Cell viability was recorded by using the TC10 automated cell counter.
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4.3. Time-Course Assay Using Cytokine IL-4 and IL-13
A time course assay was performed with an optimum concentration of n-3 and n-6 fatty acids.
Once again, the cells were cultured in five (one for each time interval) 24-well plates at a density of
~50,000 cells per well. Cells were counted using the TC10 automated cell counter. HEK-Blue cells
were pipetted into 15 mL tubes, which were centrifuged at 1200 rpm for 5 min. The supernatant was
discarded and experimental media was added to suspend the cell pellet. If required, cell tires were
reduced by adding growth medium to achieve optimum cell density. The cells were pipetted into
24-well plates (Corning, Sigma-Aldrich, St. Louis, MO, USA) at a density of ~50,000 cells per well in
a total volume of 720 µL. Concentration of fatty acids used at this stage was 90 µM, which is within
high physiological levels and the most optimum concentration of fatty acid to inhibit SEAP secretion
(established from previous section). Cells were incubated in a humidified incubator at 37 ˝C with 5%
CO2 for a period of 24 h. A total of five time-points were used to measure the effect of fatty acids on
SEAP production over a period of 24 h; 0, 6, 12, 18 and 24 h, respectively. PC’s were also setup for each
time interval, which was without fatty acid treatment. Post-incubation, 80 µL of cytokine IL-4 and IL-13
were pipetted to each treatment well at a concentration of 100 ng/mL and the plates were incubated
for 24 h to stimulate the STAT6 phosphorylation pathway. Simultaneously, the experimental media in
the wells was replaced with a fresh supply of growth medium to ensure a steady supply of nutrients
to the cells. Twenty µL of induced HEK-Blue IL-4/IL-13 cell supernatant from each treatment well was
added to a corresponding plate with 180 µL of Quanti-Blue substrate in each well. This was incubated
for a total of 3 h to detect SEAP levels. The blue color was detected using a spectrophotometer at
640nm. Cell viability was recorded by using the TC10 automated cell counter.
4.4. Statistical Analysis
The data were analysed using Microsoft Excel 2013 (Microsoft Inc., Redmond, WA, USA).
The results were analysed by Student’s t-test using a two-tailed method to determine any statistically
significant difference between the controls and treatment wells in all of the above experiments.
The statistical significance was set at p < 0.05.
5. Conclusions
Overall, treatment of HEK-Blue cells with n-3 fatty acids led to a suppression of SEAP production
through inhibition of IL-4 and IL-13 signaling pathways. These results are biologically relevant
to the development of a prophylactic treatment for allergic diseases. With n-6 fatty acids, on the
other hand, an increase in SEAP output was observed, which is consistent with previous studies.
Our study presented here opens a new corridor to research with n-3 fatty acids using a transfected
model for in vitro allergy research. DHA, EPA and DPA supplementation may offer a molecular basis
for a well-developed anti-allergic effect and, therefore, must be an essential part of our regular diet.
Although further investigation will reveal the best allergy markers that can be used for suppression,
it is clear that n-3 fatty acids may offer a great opportunity as potential natural dietary inhibitors
for allergy.
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